Copyright Reports & Markets. All rights reserved.

Global Bupivacaine Extended-Release Liposome Injection Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Bupivacaine Extended-Release Liposome Injection Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 133mg Per Vial
    • 1.3.3 266mg Per Vial
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Bupivacaine Extended-Release Liposome Injection Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Local Anesthesia
    • 1.4.3 Postoperative Analgesia
    • 1.4.4 Other
  • 1.5 Global Bupivacaine Extended-Release Liposome Injection Market Size & Forecast
    • 1.5.1 Global Bupivacaine Extended-Release Liposome Injection Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Bupivacaine Extended-Release Liposome Injection Sales Quantity (2021-2032)
    • 1.5.3 Global Bupivacaine Extended-Release Liposome Injection Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pacira Pharmaceuticals
    • 2.1.1 Pacira Pharmaceuticals Details
    • 2.1.2 Pacira Pharmaceuticals Major Business
    • 2.1.3 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Product and Services
    • 2.1.4 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pacira Pharmaceuticals Recent Developments/Updates
  • 2.2 Jiangsu Hengrui Pharm
    • 2.2.1 Jiangsu Hengrui Pharm Details
    • 2.2.2 Jiangsu Hengrui Pharm Major Business
    • 2.2.3 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Product and Services
    • 2.2.4 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Jiangsu Hengrui Pharm Recent Developments/Updates

3 Competitive Environment: Bupivacaine Extended-Release Liposome Injection by Manufacturer

  • 3.1 Global Bupivacaine Extended-Release Liposome Injection Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Manufacturer (2021-2026)
  • 3.3 Global Bupivacaine Extended-Release Liposome Injection Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Bupivacaine Extended-Release Liposome Injection by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Bupivacaine Extended-Release Liposome Injection Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Bupivacaine Extended-Release Liposome Injection Manufacturer Market Share in 2025
  • 3.5 Bupivacaine Extended-Release Liposome Injection Market: Overall Company Footprint Analysis
    • 3.5.1 Bupivacaine Extended-Release Liposome Injection Market: Region Footprint
    • 3.5.2 Bupivacaine Extended-Release Liposome Injection Market: Company Product Type Footprint
    • 3.5.3 Bupivacaine Extended-Release Liposome Injection Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Bupivacaine Extended-Release Liposome Injection Market Size by Region
    • 4.1.1 Global Bupivacaine Extended-Release Liposome Injection Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Bupivacaine Extended-Release Liposome Injection Consumption Value by Region (2021-2032)
    • 4.1.3 Global Bupivacaine Extended-Release Liposome Injection Average Price by Region (2021-2032)
  • 4.2 North America Bupivacaine Extended-Release Liposome Injection Consumption Value (2021-2032)
  • 4.3 Europe Bupivacaine Extended-Release Liposome Injection Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Consumption Value (2021-2032)
  • 4.5 South America Bupivacaine Extended-Release Liposome Injection Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 5.2 Global Bupivacaine Extended-Release Liposome Injection Consumption Value by Type (2021-2032)
  • 5.3 Global Bupivacaine Extended-Release Liposome Injection Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 6.2 Global Bupivacaine Extended-Release Liposome Injection Consumption Value by Application (2021-2032)
  • 6.3 Global Bupivacaine Extended-Release Liposome Injection Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 7.2 North America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 7.3 North America Bupivacaine Extended-Release Liposome Injection Market Size by Country
    • 7.3.1 North America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Bupivacaine Extended-Release Liposome Injection Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 8.2 Europe Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 8.3 Europe Bupivacaine Extended-Release Liposome Injection Market Size by Country
    • 8.3.1 Europe Bupivacaine Extended-Release Liposome Injection Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Bupivacaine Extended-Release Liposome Injection Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Market Size by Region
    • 9.3.1 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 10.2 South America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 10.3 South America Bupivacaine Extended-Release Liposome Injection Market Size by Country
    • 10.3.1 South America Bupivacaine Extended-Release Liposome Injection Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Bupivacaine Extended-Release Liposome Injection Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Market Size by Country
    • 11.3.1 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Bupivacaine Extended-Release Liposome Injection Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Bupivacaine Extended-Release Liposome Injection Market Drivers
  • 12.2 Bupivacaine Extended-Release Liposome Injection Market Restraints
  • 12.3 Bupivacaine Extended-Release Liposome Injection Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Bupivacaine Extended-Release Liposome Injection and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Bupivacaine Extended-Release Liposome Injection
  • 13.3 Bupivacaine Extended-Release Liposome Injection Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Bupivacaine Extended-Release Liposome Injection Typical Distributors
  • 14.3 Bupivacaine Extended-Release Liposome Injection Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Bupivacaine Extended-Release Liposome Injection market size was valued at US$ 383 million in 2025 and is forecast to a readjusted size of US$ 519 million by 2032 with a CAGR of 4.5% during review period.
    Bupivacaine liposome injection is a special formulation that encapsulates the local anesthetic bupivacaine within liposomes. This delivery system allows for prolonged and controlled release of bupivacaine, thereby extending the duration of its anesthetic effect.
    This report is a detailed and comprehensive analysis for global Bupivacaine Extended-Release Liposome Injection market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Bupivacaine Extended-Release Liposome Injection market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Bupivacaine Extended-Release Liposome Injection market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Bupivacaine Extended-Release Liposome Injection market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Bupivacaine Extended-Release Liposome Injection market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Bupivacaine Extended-Release Liposome Injection
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Bupivacaine Extended-Release Liposome Injection market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pacira Pharmaceuticals, Jiangsu Hengrui Pharm, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Bupivacaine Extended-Release Liposome Injection market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    133mg Per Vial
    266mg Per Vial
    Market segment by Application
    Local Anesthesia
    Postoperative Analgesia
    Other
    Major players covered
    Pacira Pharmaceuticals
    Jiangsu Hengrui Pharm
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Bupivacaine Extended-Release Liposome Injection product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Bupivacaine Extended-Release Liposome Injection, with price, sales quantity, revenue, and global market share of Bupivacaine Extended-Release Liposome Injection from 2021 to 2026.
    Chapter 3, the Bupivacaine Extended-Release Liposome Injection competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Bupivacaine Extended-Release Liposome Injection breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Bupivacaine Extended-Release Liposome Injection market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Bupivacaine Extended-Release Liposome Injection.
    Chapter 14 and 15, to describe Bupivacaine Extended-Release Liposome Injection sales channel, distributors, customers, research findings and conclusion.

    Buy now